PŘEHLEDOVÉ ČLÁNKY / REVIEW ARTICLES Maligní hypertermie „up‑to‑date prakticky“ – nesystematický přehledový článek 82 | ANESTEZIOLOGIE A INTENZIVNÍ MEDICÍNA / Anest intenziv Med. 2025;36(2):74-83 / www.aimjournal.cz PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Práce je původní a nebyla publikována ani není zaslána k recenznímu řízení do jiného média. Střet zájmů: Autoři prohlašují, že nemají střet zájmů v souvislosti s tématem práce. Podíl autorů: Všichni autoři rukopis četli, souhlasí s jeho zněním a zasláním do redakce časopisu Anesteziologie a intenzivní medicína. Na přípravě a revizích rukopisu se podíleli všichni autoři, DŠ a MK se podílely stejnou mírou. Financování: Tato práce byla podpořena Specifickým univerzitním výzkumem poskytovaným MŠMT (MUNI/A/1771/2024; MUNI/A/1733/2024), MZ ČR – RVO (FNBr, 65269705) a především prostředky AZV grantem MZ (NU21-06-00363). Poděkování: Děkujeme všem kolegyním a kolegům, kteří nám pacienty do centra zodpovědně hlásí a pomáhají s dohledáním relevantních informací. Velice oceňujeme, že i přes dobrovolnost je to pro vás samozřejmé. Registrace: N/A. Projednání etickou komisí: N/A. LITERATURA 1. Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare, DiS. 2015 Aug 4;10:93. 2. Malignant Hyperthermia Association of the United States. Safe and unsafe anaesthetics. [Internet]. [cited 2024 Dec 16]. Available from: https://www.mhaus.org/healthcare ‑professionals/be‑prepared/safe‑and‑unsafe‑anesthetics/. 3. Jephcott C, Grummet J, Nguyen N, Spruyt O. A review of the safety and efficacy of inhaled methoxyflurane as an analgesic for outpatient procedures. Br J Anaesth. 2018 May;120(5):1040-8. 4. Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth. 1962 Jun;34:395-6. 5. Glahn KPE, Bendixen D, Girard T, Hopkins PM, Johannsen S, Rüffert H, et al. European Malignant Hyperthermia Group. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br J Anaesth. 2020 Aug;125(2):133-40. 6. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat. 2006 Oct;27(10):977-89. 7. Carpenter D, Ringrose C, Leo V, Morris A, Robinson RL, Halsall PJ, et al. The role of CACNA1S in predisposition to malignant hyperthermia. BMC Med Genet. 2009 Oct 13;10:104. 8. European Malignant Hyperthermia Group. STAC3 variants in susceptibility to malignant hyperthermia [Internet]. EMHG. 2019 [cited 2024 Dec 16]. Available from: https:// www.emhg.org/stac3. 9. Zaharieva IT, Sarkozy A, Munot P, Manzur A, O’Grady G, Rendu J, et al. STAC3 variants cause a congenital myopathy with distinctive dysmorphic features and malignant hyperthermia susceptibility. Hum Mutat. 2018 Dec;39(12):1980-94. 10. Klincová M, Štěpánková D, Schröderová I, Klabusayová E, Ošťádalová E, Valášková I, et al. 20 let diagnostiky maligní hypertermie v České a Slovenské republice. Anest Intenziv Med. 2023;34(3):103-9. 11. Klincová M, Štěpánková D, Schröderová I, Klabusayová E, Ošťádalová E, Valášková I, et al. Malignant hyperthermia in Czechia and Slovakia. Br J Anaesth. 2022 Aug;129(2):e41-3. 12. Klingler W, Heiderich S, Girard T, Gravino E, Heffron JJ, Johannsen S, et al. Functional and genetic characterization of clinical malignant hyperthermia crises: a multi‑centre study. Orphanet J Rare, DiS. 2014 Jan 16;9:8. 13. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low ‑risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand. 1997 Sep;41(8):955-66. 14. Hopkins PM, Rüffert H, Snoeck MM, Girard T, Glahn KPE, Ellis FR, et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth. 2015 Oct;115(4):531-9. 15. European Malignant Hyperthermia Group. Diagnostic MH Mutations [Internet]. EMHG. [cited 2024 Dec 16]. Available from: https://www.emhg.org/diagnostic‑mutations. 16. Klincová M, Štěpánková D, Schröderová I, Klabusayová E, Štourač P. Malignant Hyperthermia in PICU‑From Diagnosis to Treatment in the Light of Up‑to‑Date Knowledge. Child Basel Switz. 2022 Nov 4;9(11):1692. 17. Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet Lond Engl. 1991 Dec 14;338(8781):1491-2. 18. Muldoon S, Deuster P, Voelkel M, Capacchione J, Bunger R. Exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia: is there a link? Curr Sports Med Rep. 2008 Apr;7(2):74-80. 19. Laitano O, Murray KO, Leon LR. Overlapping Mechanisms of Exertional Heat Stroke and Malignant Hyperthermia: Evidence vs. Conjecture. Sports Med Auckl NZ. 2020 Sep;50(9):1581-92. 20. Kruijt N, van den Bersselaar LR, Wijma J, Verbeeck W, Coenen MJH, Neville J, et al. HyperCKemia and rhabdomyolysis in the neuroleptic malignant and serotonin syndromes: A literature review. Neuromuscul Disord NMD. 2020 Dec;30(12):949-58. 21. van den Bersselaar LR, Kruijt N, Bongers CCWG, Jungbluth H, Treves S, Riazi S, et al. Comment on „Overlapping Mechanisms of Exertional Heat Stroke and Malignant Hyperthermia: Evidence vs. Conjecture.“ Sports Med Auckl NZ. 2022 Mar;52(3):669-72. 22. Riazi S, Kraeva N, Hopkins PM. Malignant Hyperthermia in the Post‑Genomics Era: New Perspectives on an Old Concept. Anesthesiology. 2018 Jan;128(1):168-80. 23. Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant Hyperthermia Susceptibility and Related Diseases. Anesthesiology. 2018 Jan;128(1):159-67. 24. Snoeck M, van Engelen BGM, Küsters B, Lammens M, Meijer R, Molenaar JPF, et al. RYR1-related myopathies: a wide spectrum of phenotypes throughout life. Eur J Neurol. 2015 Jul;22(7):1094-112. 25. Bamaga AK, Riazi S, Amburgey K, Ong S, Halliday W, Diamandis P, et al. Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: A 25-year retrospective study. Neuromuscul Disord NMD. 2016 Mar;26(3):201-6. 26. Gupta PK, Bilmen JG, Hopkins PM. Anaesthetic management of a known or suspected malignant hyperthermia susceptible patient. BJA Educ [Internet]. 2021 Jun 1. 21(6):218-24. [cited 2024 Dec 16]. Available from: https://www.bjaed.org/article/S2058-5349(21)000068/fulltext. 27. Ibarra Moreno CA, Silva HCA, Voermans NC, Jungbluth H, van den Bersselaar LR, Rendu J, et al. Myopathic manifestations across the adult lifespan of patients with malignant hyperthermia susceptibility: a narrative review. Br J Anaesth. 2024 Oct;133(4):759-67. 28. Schieren M, Defosse J, Böhmer A, Wappler F, Gerbershagen MU. Anaesthetic management of patients with myopathies. Eur J Anaesthesiol. 2017 Oct;34(10):641-9. 29. van den Bersselaar LR, Hellblom A, Gashi M, Kamsteeg EJ, Voermans NC, Jungbluth H, et al. Referral Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next‑generation Sequencing. Anesthesiology. 2022 Jun 1;136(6):940-53. 30. Rüffert H, Bastian B, Bendixen D, Girard T, Heiderich S, Hellblom A, et al. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2021 Jan;126(1):120-30. 31. Hopkins PM, Girard T, Dalay S, Jenkins B, Thacker A, Patteril M, et al. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. Anaesthesia. 2021 May;76(5):655-64. 32. Glahn KPE, Ellis FR, Halsall PJ, Müller CR, Snoeck MMJ, Urwyler A, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010 Oct;105(4):417-20. 33. Glahn KPE, Girard T, Hellblom A, Hopkins P, Johannsen S, Rueffert H, et al. Recognition and management of a malignant hyperthermia crisis: updated 2024 guideline from the European Malignant Hyperthermia Group. Br J Anaesth. 2025 Jan;134(1):221-223. 34. Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth. 2011 Jul;107(1):48-56. 35. Targ AG, Yasuda N, Eger II EI. Solubility of I-653, sevoflurane, isoflurane, and halothane in plastics and rubber composing a conventional anesthetic circuit. Anesth Analg. 1989;69(2):218-25. 36. Bilmen JG, Hopkins PM. The use of charcoal filters in malignant hyperthermia: have they found their place? Anaesthesia. 2019 Jan;74(1):13-6. 37. Bilmen JG, Gillies RL. Clarifying the Role of Activated Charcoal Filters in Preparing an Anaesthetic Workstation for Malignant Hyperthermia – Susceptible Patients. Anaesth Intensive Care [Internet]. 2014 Jan 1 42(1):51-8. [cited 2024 Dec 16]. Available from: https:// doi.org/10.1177/0310057X1404200110. 38. Wappler F. Anaesthesia recommendations for Malignant hyperthermia. [Internet]. [cited 2024 Dec 16]. Available from: https://www.orphananesthesia.eu/en/rare‑diseases/ published‑guidelines/malignant‑hyperthermia/958-malignant‑hyperthermia-2/file.html. 39. Fuchs‑Buder T, Romero CS, Lewald H, Lamperti M, Afshari A, Hristovska AM, et al. Peri ‑operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol EJA [Internet]. 2023 Feb [cited 2024 Dec 16]. Available from: https://journals.lww.com/ejanaesthesiology/Fulltext/2023/02000/Peri_operative_management_of_neuromuscular.3.aspx. 40. Overview | Depth of anaesthesia monitors – Bispectral Index (BIS), E‑Entropy and Narcotrend‑Compact M | Guidance | NICE [Internet]. NICE; 2012 [cited 2024 Dec 16]. Available from: https://www.nice.org.uk/guidance/dg6. 41. Adamus M, Cvachovec K, Černý V, Herold I, Horáček M, Mach D, et al. Zásady bezpečné anesteziologické péče [Internet]. ČSARIM; 2017 [cited 2024 Dec 16]. Available from: https://
RkJQdWJsaXNoZXIy NDA4Mjc=